Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Posted: September 16, 2022 at 2:43 am

CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Link:
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Related Posts